Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Multiple Myeloma”

806 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 806 results

Early research (Phase 1)Not Yet RecruitingNCT07113496
What this trial is testing

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Who this might be right for
Relapsed or Refractory B-cell Hematologic MalignanciesB-cell Acute Lymphoblastic Leukemia (B-ALL)Multiple Myeloma (MM)+3 more
The First Affiliated Hospital with Nanjing Medical University 27
Early research (Phase 1)Looking for participantsNCT05652335
What this trial is testing

JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Who this might be right for
Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC 180
Not applicableUnknownNCT00295997
What this trial is testing

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Who this might be right for
Chronic Myeloproliferative DisordersKidney CancerLeukemia+4 more
University of California, San Francisco 35
Testing effectiveness (Phase 2)Study completedNCT02206425
What this trial is testing

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
Oncotherapeutics 45
Large-scale testing (Phase 3)Study completedNCT00657488
What this trial is testing

Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 400
Early research (Phase 1)Study completedNCT04671251
What this trial is testing

Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Avalo Therapeutics, Inc. 13
Testing effectiveness (Phase 2)Ended earlyNCT00765102
What this trial is testing

Trial of Romidepsin and Bortezomib for Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 32
Very early researchUnknownNCT04156269
What this trial is testing

BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
iCell Gene Therapeutics 12
Testing effectiveness (Phase 2)Looking for participantsNCT07410494
What this trial is testing

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
CancerBreast CancerNon-Small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech 85
Early research (Phase 1)Ended earlyNCT04272775
What this trial is testing

MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma
Takeda 14
Testing effectiveness (Phase 2)Study completedNCT02410694
What this trial is testing

Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Arbeitsgemeinschaft medikamentoese Tumortherapie 90
Large-scale testing (Phase 3)Study completedNCT03234972
What this trial is testing

Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 213
Very early researchLooking for participantsNCT06718270
What this trial is testing

CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia

Who this might be right for
Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Plasma Cell Leukemia
Shanghai Changzheng Hospital 24
Early research (Phase 1)Study completedNCT00569283
What this trial is testing

Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant

Who this might be right for
Cancer
Asan Medical Center 18
Testing effectiveness (Phase 2)Study completedNCT00618345
What this trial is testing

Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Mayo Clinic 35
Early research (Phase 1)Active Not RecruitingNCT05286229
What this trial is testing

Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan

Who this might be right for
Relapsed/Refractory Multiple Myeloma
AbbVie 8
Early research (Phase 1)Study completedNCT01359657
What this trial is testing

Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 46
Early research (Phase 1)UnknownNCT05052970
What this trial is testing

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

Who this might be right for
Relapsed or Refractory Multiple Myeloma
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. 60
Testing effectiveness (Phase 2)WithdrawnNCT01329289
What this trial is testing

SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma
University of Pittsburgh
Early research (Phase 1)Ended earlyNCT04895410
What this trial is testing

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

Who this might be right for
Multiple Myeloma
AbbVie 8
Load More Results